MLYS NASDAQ
Mineralys Therapeutics, Inc.
1W: -8.6%
1M: -18.6%
3M: -18.9%
YTD: -33.8%
1Y: -40.6%
3Y: +139.9%
$23.63
-0.09 (-0.38%)
Weekly Expected Move ±9.1%
$19
$21
$24
$26
$28
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.1B
52W Range22.3-47.65
Volume927,286
Avg Volume1,343,422
Beta0.68
Dividend—
Analyst Ratings
Company Info
CEOJon Congleton
Employees76
SectorHealthcare
IndustryBiotechnology
IPO Date2023-02-10
Websitemineralystx.com
150 N. Radnor Chester Rd.
Radnor, PA 19087
US
Radnor, PA 19087
US
888-378-6240
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Latest News
Mineralys Therapeutics (NASDAQ:MLYS) Director Brian Taylor Slingsby Sells 104,320 Shares of Company Stock
Mineralys Therapeutics (NASDAQ:MLYS) Insider Eric Warren Sells 7,438 Shares
Bank of America Corp DE Takes Position in Mineralys Therapeutics, Inc. $MLYS
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Director Sells $85,740.00 in Stock
Legal & General Group Plc Purchases New Shares in Mineralys Therapeutics, Inc. $MLYS
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Congleton Jon | S-Sale | 75,000 | $25.46 | 2026-09-30 |
| Slingsby Brian Taylo | S-Sale | 104,320 | $28.81 | 2026-09-22 |
| Warren Eric | M-Exempt | 7,438 | $13.24 | 2026-09-21 |
| Warren Eric | S-Sale | 7,438 | $28.12 | 2026-09-21 |
| Warren Eric | M-Exempt | 7,438 | $13.24 | 2026-09-21 |